Related Experiment Video
Updated: Apr 16, 2026

Author Spotlight: An Economic and Efficient Method for Quantitative Evaluation of Bone Microarchitecture in a Murine Osteoporosis Model
Published on: September 8, 2023
Long-term follow-up of bone density in women with primary ovarian insufficiency
Cristina Laguna Benetti-Pinto1, Valeska B Ferreira, Daniela A Yela
11Department of Gynecology and Obstetrics, School of Medical Sciences, State University of Campinas, Campinas, São Paulo, Brazil 2School of Medical Sciences, State University of Campinas, Brazil.
Objective:
This study aims to analyze long-term variation in bone mineral density among young women with primary ovarian insufficiency.
Methods:
A cohort study evaluated bone mineral density in 72 women with primary ovarian insufficiency who were receiving estrogen + progestogen therapy. Bone mineral density was evaluated every 2 years for 8 years.
Results:
The women were young, with a mean (SD) age of 34.1 (6.7) years and had a bone density measurement at baseline. The mean (SD) time between the last menstruation and the beginning of hormone treatment was 2.9 (4.2) years. The initial mean (SD) bone mineral density was 1.03 (0.17) and 0.91 (0.16) g/cm for the lumbar spine and femoral neck, respectively. The mean (SD) T score was -1.03 (1.39) and -0.29 (1.09) for the lumbar spine and femoral neck, respectively. Bone mineral density measurements after a follow-up period of 2, 4, 6, and 8 years did not differ from bone mineral density at baseline. Osteopenia and osteoporosis were observed at the lumbar spine and femoral neck in 46% and 25% of women at the time of diagnosis, with no difference in the percentage of affected women across time.
Conclusions:
Although women with primary ovarian insufficiency who are receiving estrogen + progestogen therapy maintain stable bone mass throughout an 8-year follow-up period, this treatment is not sufficient to decrease the number of women who experience some level of low bone density. Therapeutic regimens should be reviewed, probably with resumption of discussions about the need for other therapeutic strategies.
More Related Videos
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...

